Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Int J Toxicol ; 32(2): 123-9, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23358464

RESUMEN

The estrogenic potential of lavender oil was evaluated in a percutaneous uterotrophic bioassay in immature female rats. Four groups of 10 immature female rats each were randomly selected on postpartum day (PPD) 16. During the 3-day treatment period (PPDs 19-21), the immature rats were separated from the dams, caged in groups of 5 in a litter box for 6 hours, and administered the vehicle control article (corn oil) or lavender oil at 20 or 100 mg/kg per day. All dosages were administered as a 5 mL/kg volume in a Hilltop Chamber (25 mm diameter; absorbent material removed) placed on the shaved back of each immature rat, and secured with micropore tape and Vetrap. A positive control group was gavaged twice daily with 2.5 µg/kg per day of 17α-ethinyl estradiol. Daily observations included viability, clinical signs, body weights, and body weight gains. All rats were euthanized 24 hours after the third and final treatment, the uteri and ovaries were removed, and the paired ovaries and wet and blotted uterine weights were recorded. No unscheduled deaths occurred. No skin reactions were observed. Both dosages of lavender oil significantly reduced body weight gains after the third day of treatment, but terminal body weights and mean absolute and relative uterine weights did not differ significantly from vehicle control values. Positive controls showed significant increases in body weight and increased mean absolute and relative uterine weights as expected. Based on these data, lavender oil, at dosages of 20 or 100 mg/kg, was not active in the rat uterotrophic assay and gave no evidence of estrogenic activity.


Asunto(s)
Estrógenos/efectos adversos , Aceites Volátiles/efectos adversos , Aceites de Plantas/efectos adversos , Absorción Cutánea , Útero/efectos de los fármacos , Administración Cutánea , Animales , Aceite de Maíz/administración & dosificación , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Estrógenos/administración & dosificación , Etinilestradiol/administración & dosificación , Femenino , Lavandula , Aceites Volátiles/administración & dosificación , Tamaño de los Órganos/efectos de los fármacos , Ovario/efectos de los fármacos , Ovario/patología , Aceites de Plantas/administración & dosificación , Periodo Posparto/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Útero/patología , Aumento de Peso/efectos de los fármacos
2.
Regul Toxicol Pharmacol ; 63(1): 29-39, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22343256

RESUMEN

Anidulafungin and voriconazole are potent antifungal agents that may provide a powerful therapeutic option over current therapies when coadministered. A non-clinical combination toxicity study was required as part of the voriconazole Paediatric Investigation Plan. Rats received anidulafungin or voriconazole alone or in combination once daily from postnatal day (PND) 21-56 with a recovery period to PND 84. Doses used were based upon the approximate adult rat no observed adverse-effect level (NOAEL). Transient and reversible reductions in bodyweight, haematology, serum chemistry, liver weight and minimal liver changes were associated with anidulafungin. Voriconazole caused an increase in gamma-glutamyltransferase in female rats only. No increased toxicity was observed with the combination. Toxicokinetics were determined using a validated dual-analyte bioanalytical method. Systemic exposure at juvenile rat NOAELs was comparable to that found with adult rats in previous studies. There were no drug-drug interactions affecting exposure of either drug. Juvenile rats were not more sensitive to each drug dosed alone compared with adult rat data on the single drugs. No novel, additive or synergistic toxicities were noted with the combination in juvenile rats. This study will support future studies of the combination of voriconazole and anidulafungin in children with invasive fungal infection.


Asunto(s)
Antifúngicos/farmacocinética , Antifúngicos/toxicidad , Equinocandinas/farmacocinética , Equinocandinas/toxicidad , Pirimidinas/farmacocinética , Pirimidinas/toxicidad , Triazoles/farmacocinética , Triazoles/toxicidad , Administración Oral , Anidulafungina , Animales , Antifúngicos/administración & dosificación , Área Bajo la Curva , Combinación de Medicamentos , Evaluación Preclínica de Medicamentos/métodos , Equinocandinas/administración & dosificación , Femenino , Inyecciones Subcutáneas , Masculino , Pirimidinas/administración & dosificación , Ratas , Ratas Endogámicas F344 , Proyectos de Investigación , Factores Sexuales , Pruebas de Toxicidad/métodos , Triazoles/administración & dosificación , Voriconazol
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA